Identification of Prognostic Genes in Gliomas Based on Increased Microenvironment Stiffness.
Chaang-Ray ChenRong-Shing ChangChi-Shuo ChenPublished in: Cancers (2022)
With a median survival time of 15 months, glioblastoma multiforme is one of the most aggressive primary brain cancers. The crucial roles played by the extracellular matrix (ECM) stiffness in glioma progression and treatment resistance have been reported in numerous studies. However, the association between ECM-stiffness-regulated genes and the prognosis of glioma patients remains to be explored. Thus, using bioinformatics analysis, we first identified 180 stiffness-dependent genes from an RNA-Seq dataset, and then evaluated their prognosis in The Cancer Genome Atlas (TCGA) glioma dataset. Our results showed that 11 stiffness-dependent genes common between low- and high-grade gliomas were prognostic. After validation using the Chinese Glioma Genome Atlas (CGGA) database, we further identified four stiffness-dependent prognostic genes: FN1, ITGA5, OSMR, and NGFR. In addition to high-grade glioma, overexpression of the four-gene signature also showed poor prognosis in low-grade glioma patients. Moreover, our analysis confirmed that the expression levels of stiffness-dependent prognostic genes in high-grade glioma were significantly higher than in low-grade glioma, suggesting that these genes were associated with glioma progression. Based on a pathophysiology-inspired approach, our findings illuminate the link between ECM stiffness and the prognosis of glioma patients and suggest a signature of four stiffness-dependent genes as potential therapeutic targets.
Keyphrases
- high grade
- low grade
- bioinformatics analysis
- genome wide
- poor prognosis
- extracellular matrix
- genome wide identification
- end stage renal disease
- ejection fraction
- newly diagnosed
- rna seq
- prognostic factors
- chronic kidney disease
- genome wide analysis
- dna methylation
- squamous cell carcinoma
- emergency department
- gene expression
- patient reported outcomes
- risk assessment
- binding protein
- patient reported